Evaluating the effectiveness of laser treatment for glaucoma patients
Efficacy of Direct Selective Laser Trabeculoplasty in Clinical Practice in Patients with Glaucoma
This study tests whether a new laser treatment can help lower eye pressure in people with open-angle glaucoma over the course of a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Clínica Rementería Academic / other |
| Locations | 1 site (Madrid, Madrid) |
| Trial ID | NCT06808633 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with open-angle glaucoma who are scheduled to receive direct selective laser trabeculoplasty (DSLT) treatment. The study will monitor the impact of DSLT on intraocular pressure (IOP) over a 12-month period, with follow-up visits at one week, one month, three months, six months, and twelve months post-treatment. The treatment involves applying 120 laser pulses using the Voyager DSLT system to reduce IOP in patients who are not on hypotensive medication. The study aims to gather data on the efficacy of this laser treatment in a clinical setting.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old diagnosed with open-angle glaucoma and scheduled for bilateral laser treatment.
Not a fit: Patients with uveitis, angle closure glaucoma, or those who have had recent intraocular surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for lowering intraocular pressure in glaucoma patients.
How similar studies have performed: Previous studies have shown promising results with laser treatments for glaucoma, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Age over 18 years • Diagnosis of open angle glaucoma in eye study and scheduled for both eyes being treated after bilateral laser indication. The diagnosis of glaucoma will be based on the presence of optic nerve damage that is compatible with glaucoma in the absence of any other cause that could have produced this damage, with an IOP value\>21 mmHg. Exclusion Criteria: * Patients diagnosed with uveitis, angle closure or congenital glaucoma. * Presence of anterior peripheral synechiae * Patients unable to complete three, six- and 12-months follow-up. * Patients having undergone intraocular surgery, save for uneventful phacoemulsification (performed at least 6 months prior to inclusion)
Where this trial is running
Madrid, Madrid
- Clínica Rementería — Madrid, Madrid, Spain (Recruiting)
Study contacts
- Study coordinator: Inés Contreras
- Email: contreras@clinicarementeria.es
- Phone: +34913083838
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.